Imperial College London
Portrait Picture

DrBrijeshPatel

Faculty of Medicine, Department of Surgery & Cancer

Clinical Senior Lecturer in Cardiothoracic
 
 
 
//

Contact

 

+44 (0)20 3315 8897brijesh.patel Website

 
 
//

Location

 

Adult Intensive Care UnitSydney StreetRoyal Brompton Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Garfield:2021:10.1097/MAT.0000000000001527,
author = {Garfield, B and Bianchi, P and Arachchillage, D and Hartley, P and Naruka, V and Shroff, D and Law, A and Passariello, M and Patel, B and Price, S and Rosenberg, A and Singh, S and Trimlett, R and Xu, T and Doyle, J and Ledot, S},
doi = {10.1097/MAT.0000000000001527},
journal = {ASAIO Journal},
pages = {982--988},
title = {Six month mortality in patients with COVID-19 and non-COVID-19 viral pneumonitis managed with veno-venous extracorporeal membrane oxygenation},
url = {http://dx.doi.org/10.1097/MAT.0000000000001527},
volume = {67},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - A significant proportion of patients with COVID-19 develop acute respiratory distress syndrome (ARDS) with high risk of death. The efficacy of veno-venous extracorporeal membrane oxygenation (VV-ECMO) for COVID-19 on longer-term outcomes, unlike in other viral pneumonias, is unknown. In this study, we aimed to compare the 6 month mortality of patients receiving VV-ECMO support for COVID-19 with a historical viral ARDS cohort. Fifty-three consecutive patients with COVID-19 ARDS admitted for VV-ECMO to the Royal Brompton Hospital between March 17, 2020 and May 30, 2020 were identified. Mortality, patient characteristics, complications, and ECMO parameters were then compared to a historical cohort of patients with non-COVID-19 viral pneumonia. At 6 months survival was significantly higher in the COVID-19 than in the non-COVID-19 viral pneumonia cohort (84.9% vs. 66.0%, p = 0.040). Patients with COVID-19 had an increased Murray score (3.50 vs. 3.25, p = 0.005), a decreased burden of organ dysfunction (sequential organ failure score score [8.76 vs. 10.42, p = 0.004]), an increased incidence of pulmonary embolism (69.8% vs. 24.5%, p < 0.001) and in those who survived to decannulation longer ECMO runs (19 vs. 11 days, p = 0.001). Our results suggest that survival in patients supported with EMCO for COVID-19 are at least as good as those treated for non-COVID-19 viral ARDS.
AU  - Garfield,B
AU  - Bianchi,P
AU  - Arachchillage,D
AU  - Hartley,P
AU  - Naruka,V
AU  - Shroff,D
AU  - Law,A
AU  - Passariello,M
AU  - Patel,B
AU  - Price,S
AU  - Rosenberg,A
AU  - Singh,S
AU  - Trimlett,R
AU  - Xu,T
AU  - Doyle,J
AU  - Ledot,S
DO  - 10.1097/MAT.0000000000001527
EP  - 988
PY  - 2021///
SN  - 1058-2916
SP  - 982
TI  - Six month mortality in patients with COVID-19 and non-COVID-19 viral pneumonitis managed with veno-venous extracorporeal membrane oxygenation
T2  - ASAIO Journal
UR  - http://dx.doi.org/10.1097/MAT.0000000000001527
UR  - https://www.ncbi.nlm.nih.gov/pubmed/34144551
UR  - http://hdl.handle.net/10044/1/91721
VL  - 67
ER  -
Download